Scientific publications

Cagrilintide plus semaglutide for obesity management

May 8, 2021 | Magazine: The Lancet

Sara Becerril  1 , Gema Frühbeck  2

Despite the huge prevalence of obesity worldwide, approved pharmacological treatment options are scarce and do not satisfactorily bridge the gap in efficacy between lifestyle behavioural changes and bariatric surgery to attain sustained long-term results. 1

Combination therapy in diabetes and hypertension treatment is commonplace in most high-income countries; 2 ,  3 however, in obesity few options are generally available. Interestingly, some of the most promising anti-obesity candidates for dual therapy are co-agonists of the gut hormones GLP-1, glucagon, amylin, and gastric inhibitory peptide. 4

CITATION  Lancet. 2021 May 8;397(10286):1687-1689. doi: 10.1016/S0140-6736(21)00944-2.  Epub 2021 Apr 22.